Related Experiment Video
Updated: Jul 5, 2025

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
Published on: May 16, 2021
The European Lead Factory: Results from a decade of collaborative, public-private, drug discovery programs
Herman van Vlijmen1, Andrew D Pannifer2, Phil Cochrane3
1Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
Abstract:
The European Lead Factory (ELF) is a consortium of universities and small and medium-sized enterprises (SMEs) dedicated to drug discovery, and the pharmaceutical industry. This unprecedented consortium provides high-throughput screening, triage, and hit validation, including to non-consortium members. The ELF library was created through a novel compound-sharing model between nine pharmaceutical companies and expanded through library synthesis by chemistry-specialized SMEs. The library has been screened against ∼270 different targets and 15 phenotypic assays, and hits have been developed to form the basis of patents and spin-off companies. Here, we review the outcome of screening campaigns of the ELF, including the performance and physicochemical properties of the library, identification of possible frequent hitter compounds, and the effectiveness of the compound-sharing model.
Related Concept Videos
Drug Discovery: Overview
Preclinical Development: Overview
Clinical Trials: Overview
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Regulation
Drug Nomenclature

